MAPS' recent economic study revealed huge cost savings from MDMA-assisted therapy to treat PTSD. But that could be just the beginning of the savings.
MAPS Study: MDMA-Assisted Psychotherapy Will Be More Cost-Effective than Other Treatments for PTSD
MDMA-assisted psychotherapy for PTSD is estimated to produce cost savings of $103,200 per patient, over a 30-year treatment horizon.
The 4 Best-Performing Psychedelic Stocks
As the new rally in psychedelic stocks progresses, these four companies are currently setting the pace.
Numinus First Canadian Public Company to Complete Legal Harvest of Psilocybe Mushrooms
Numinus announces its first psilocybin harvest and the appointment of a new Science Officer.
Field Trip Health Ltd. Continues Expansion With Psychedelic-Enhanced Therapy Center in Chicago
Field Trip Health opens a new clinic in Chicago, its 4th ketamine-assisted psychotherapy clinic.
How and Why Psychedelic Drugs Can Conquer The Mental Health Crisis
An enormous Crisis. Huge treatment markets. Massive disruption potential. Welcome to the psychedelic drug industry.
Psyched Wellness Ltd. to Commence Trading on the CSE on October 22, 2020
The latest psychedelic drug company to commence public trading is Psyched Wellness.
Mind Cure’s New Medtech Platform Is A Critical Puzzle-Piece
With its new digital therapeutics platform, Mind Cure is positioning itself as an emerging leader in the psychedelic drug industry.
Mind Cure Announces LOI for Acquisition of Epiphany360 Digital Therapeutics Platform for Treating Mental Health
Mind Cure has acquired Epiphany360, a digital therapeutics platform for the treatment of mental health conditions.
Pharmather Files for FDA Orphan Drug Designation for Ketamine in Parkinson's Disease
Pharmather is seeking to advance a ketamine-based therapy for the treatment of Parkinson's disease.
Revive Therapeutics Signs Supply Agreement With Havn Life Sciences for Psychedelic Compounds
Revive has signed a psychedelics supply agreement with HAVN Life Sciences.
Why Psychedelic Stocks Are A Strong Hedge Against COVID-19 Risk
Psychedelic drug stocks may represent the best investing strategy to hedge against COVID-19 economic risks.
